2013
Career Path Seminar, Entrepreneurship at Beijing Yizhuang Biomedical Park
We invite youto join the following Career Path Seminar this Friday:
Entrepreneurship at Beijing Yizhuang Biomedical Park
–the opportunities and challenges for an overseas returnee
When: 2:30pm-4:30pm, Friday, Sept. 20, 2013
Where: Dana-Farber Cancer Institute, Yawkey Center 307, 450 Brookline Ave, Boston, MA 02215
Xiaobing Wu, PhD, Deputy General Manager, Beijing Yizhuang Biomedical Park
Light refreshment will be provided.
Sponsor: Antagen Biotechnologies
Xiaobing Wu, PhD, Deputy General Manager, Beijing Yizhuang Biomedical Park
吴小兵博士 副总裁, 北京亦庄生物医药园
Title: Introduction of Beijing Yizhuang Biomedical Park
Dr. Wu has studies viral vectors (AAV etc) and their medical applications at CDC (Chinese Disease and Control) before she joined Bejing Yizhuang Biomedical Park (BYBP) in 2011 as Vice General Manager. At BYBP, Dr. Wu mainly focuses on the setup of general technology and communication platforms including ZGC (中关村) Sino-American Bioindustrial Cluster Innovation Alliance (SABCI). The BYBP delegation visit Boston area to explore opportunities to network and collaborate with local biomedical organizations and biopharmaceutical companies as a first step to set up a platform for SABCI. Dr. Wu will introduce BYBP first followed by a talk about AAV as viral vectors in clinical applications.
吴小兵博士在2011年加盟北京亦庄生物医药园之前，主要从事病毒载体（AAV等）的研究和临床应用。自2011，年吴博士主要负责建设园区的公共技术平台和交流平台（产业论坛），包括新近成立的“中关村美中生物技术产业集群创新联盟”（ZGC Sino-American Bioindustrial Cluster Innovation Alliance, SABCI) ,其旨在促进生物技术企业之间以及和国外生物医药园区之间的交流与合作。吴博士将会着重介绍北京亦庄生物医药园，以及她的研究课题AAV病毒载体在另床上的应用。
Gao Wenda, PhD,President / Gary Xue, PhD, CEO, Antagen Biotechnologies Inc.,Beijing （BYBP）
Title: Build a biopharmaceutical company in China- take Antagen Biotechnologies Inc.as an example.
Wenda Gao, a former Assistant Professor in Beth Israel Deaconess Medical Center, Harvard Medical School, has been working on the areas of T helper cell differentiation and transplant tolerance. His findings that TGF-beta and proinflammatory cytokines (IL-4, IL-6, and IL-21) reciprocally regulate the differentiation of Treg and T effector cells opened a new field in T cell development. On the front of translational medicine, he studied tolerance induction strategies in islet transplantation models. He has been working to set up a novel mammalian expression system to meet the clinical demand of producing therapeutic proteins at low cost. This effort led to his co-founding of Antagen Biotechnologies, Inc in Beijing (at BYBP). They will talk about their experience in building the startup biopharmaceutical company Antagen Biotechnologies Inc. at BYBP.
共同创建安泰吉（北京）生物技术有限公司之前，高闻达博士在哈佛大学医学院担任助理教授，主要从事T helper细胞的分化及其在器官移植（耐受）方面的应用。他在TGF-beta和炎症细胞因子 (IL-4, IL-6, and IL-21)交互调控Treg和T effector 分化方面的研究（two Nature papers）打开了T helper细胞分化研究的新领域。数年前，高博士在器官移植耐受转化医学领域的兴趣最终导致了安泰吉（北京）的创立。高闻达博士将介绍公司的建立和发展情况以及公司的主要技术平台。